Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

Rslcan18 Inhibitors

The class of Rslcan18 Inhibitors, encompasses a wide array of chemical compounds designed to indirectly modulate the activity or expression of the protein encoded by the Rslcan18 gene. This indirect approach relies on influencing key signaling pathways and regulatory mechanisms within the cell that Rslcan18 might be part of or influence, including PI3K/AKT, MAPK/ERK, and mTOR pathways, as well as processes related to protein degradation and gene expression regulation.

By targeting these cellular pathways and processes, the inhibitors can affect the functional context within which Rslcan18 operates, thereby modulating its activity or regulatory mechanisms. For example, kinase inhibitors like Staurosporine and specific pathway inhibitors such as LY294002 for PI3K, U0126 and PD98059 for MEK, and Rapamycin for mTOR offer insights into the complex regulatory networks governing cellular function and the potential roles of Rslcan18 within these networks. Moreover, the inclusion of compounds affecting gene expression and protein stability, such as Trichostatin A for histone deacetylation and Bortezomib for proteasome-mediated protein degradation, highlights the multifaceted strategies through which cellular signaling and function can be modulated.

This approach underscores the potential of pharmacological interventions to explore and influence the function of proteins like Rslcan18, providing a framework for understanding the interplay between chemical compounds and biological processes. Through their action, the inhibitors classified within the Rslcan18 Inhibitors group not only illuminate the potential mechanisms regulating Rslcan18 but also offer a broader perspective on the modulation of cellular signaling pathways, protein activity, and gene expression. This conceptual exploration emphasizes the complexity of cellular regulation and the potential for indirect modulation of specific protein functions through targeted pharmacological interventions, highlighting the intricate web of interactions that govern cellular signaling, regulation, and the response to external stimuli.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

A broad-spectrum kinase inhibitor, can disrupt multiple signaling pathways potentially regulated by Rslcan18.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Inhibits PI3K, potentially affecting PI3K/AKT signaling pathways and indirectly modulating Rslcan18's activity or regulation.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

p38 MAPK inhibitor, can influence stress response signaling pathways possibly connected to Rslcan18's function.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

MEK inhibitor, can affect MAPK/ERK signaling, potentially altering pathways that Rslcan18 may influence.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

Another MEK inhibitor, can modify MAPK/ERK signaling pathways and potentially impact Rslcan18's regulatory mechanisms.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, potentially modulating stress and apoptosis pathways that could intersect with Rslcan18's role.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

mTOR inhibitor, affecting cell growth and proliferation pathways that Rslcan18 may be involved in.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Histone deacetylase inhibitor, can change chromatin structure and gene expression, possibly affecting Rslcan18.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor, could indirectly affect the degradation of proteins regulated by Rslcan18.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

EGFR tyrosine kinase inhibitor, could modulate signaling pathways potentially relevant to Rslcan18's role in cellular signaling.